MX2019003093A - Formas cristalinas. - Google Patents
Formas cristalinas.Info
- Publication number
- MX2019003093A MX2019003093A MX2019003093A MX2019003093A MX2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- pharmaceutical compositions
- phosphono
- enyl
- pyrrolidin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención se relaciona a formas cristalinas de clorhidrato de éster butílico del ácido 4-((R)-2-{[6-((S)-3-metoxi-pirrolidina-1- iI)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-pip erazin-1-carboxílico, procesos para la preparación de las mismas, composiciones farmacéuticas que comprenden las formas cristalinas, composiciones farmacéuticas preparadas de las formas cristalinas y sus uso como un medicamento, especialmente como un antagonista del receptor P2Y12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072562 | 2016-09-22 | ||
| PCT/EP2017/073858 WO2018055016A1 (en) | 2016-09-22 | 2017-09-21 | Crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003093A true MX2019003093A (es) | 2019-07-18 |
Family
ID=59923448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003093A MX2019003093A (es) | 2016-09-22 | 2017-09-21 | Formas cristalinas. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10730896B2 (es) |
| EP (2) | EP3515924B1 (es) |
| JP (1) | JP7097369B2 (es) |
| KR (1) | KR102552795B1 (es) |
| CN (1) | CN109715639B (es) |
| AU (1) | AU2017331930B2 (es) |
| BR (1) | BR112019004845A2 (es) |
| CA (1) | CA3037794A1 (es) |
| CL (1) | CL2019000728A1 (es) |
| CY (1) | CY1125052T1 (es) |
| DK (1) | DK3515924T3 (es) |
| EA (1) | EA201990723A1 (es) |
| ES (1) | ES2908572T3 (es) |
| HR (1) | HRP20220234T1 (es) |
| HU (1) | HUE057772T2 (es) |
| IL (1) | IL265445B2 (es) |
| LT (1) | LT3515924T (es) |
| MA (1) | MA46266B1 (es) |
| MX (1) | MX2019003093A (es) |
| MY (1) | MY193080A (es) |
| PH (1) | PH12019500567A1 (es) |
| PL (1) | PL3515924T3 (es) |
| PT (1) | PT3515924T (es) |
| RS (1) | RS62946B1 (es) |
| SI (1) | SI3515924T1 (es) |
| TW (1) | TWI752086B (es) |
| UA (1) | UA124073C2 (es) |
| WO (1) | WO2018055016A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595666A1 (en) | 2017-03-15 | 2020-01-22 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| KR20230041732A (ko) | 2020-07-15 | 2023-03-24 | 이도르시아 파마슈티컬스 리미티드 | P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물 |
| CA3223733A1 (en) | 2021-07-13 | 2023-01-19 | Nicole Blumer | A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| EP1192132B1 (en) | 1999-06-14 | 2005-09-07 | Eli Lilly And Company | Serine protease inhibitors |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| JP4662777B2 (ja) | 2002-12-11 | 2011-03-30 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 血小板アデノシン二リン酸受容体アンタゴニストとしての２−アミノカルボニルキノリン化合物 |
| PL1611144T3 (pl) | 2003-04-09 | 2011-03-31 | Wyeth Llc | Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA) |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CN101300241A (zh) | 2005-10-21 | 2008-11-05 | 埃科特莱茵药品有限公司 | 作为抗疟疾剂的哌嗪衍生物 |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| JP5309131B2 (ja) | 2007-04-23 | 2013-10-09 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのキノリン−カルボキサミド誘導体 |
| DK2225253T3 (da) * | 2007-11-29 | 2012-08-27 | Actelion Pharmaceuticals Ltd | Phosphonsyrederivater og deres anvendelse som p2y12- receptorantagonister |
| JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| CA2756542C (en) | 2009-04-08 | 2017-08-22 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
| CN102405220B (zh) | 2009-04-22 | 2015-05-27 | 埃科特莱茵药品有限公司 | 噻唑衍生物及其作为p2y12受体拮抗剂的用途 |
| EP3595666A1 (en) | 2017-03-15 | 2020-01-22 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
-
2017
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 MX MX2019003093A patent/MX2019003093A/es unknown
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/en active Active
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active IP Right Grant
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/en unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 CA CA3037794A patent/CA3037794A1/en active Pending
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 BR BR112019004845A patent/BR112019004845A2/pt unknown
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/en not_active Withdrawn
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
-
2019
- 2019-03-15 PH PH12019500567A patent/PH12019500567A1/en unknown
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US20220275011A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551089A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| MX369798B (es) | Derivados macrociclicos de pirimidina. | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| PH12017500451A1 (en) | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide | |
| PH12019500567A1 (en) | Crystalline forms | |
| WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
| WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
| EP3248603A4 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. | |
| PH12018500505A1 (en) | Crystalline forms | |
| WO2016165205A8 (zh) | 一种新型的bcr-abl激酶抑制剂 | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| GR1008380B (el) | Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου |